Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 1/20 | 0.45 |
| ▸ | NTSR1 | P30989 | 17/20 | 0.43 |
| ▸ | GBA1 | P04062 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4415044 | 0.85 | NPC1 (0.55) | GBA1 | |
| SCHEMBL4416406 | 0.84 | KDM4E (0.44) | GRM2 | |
| SCHEMBL4416527 | 0.80 | GRM2 (0.41) | GRM2 | |
| SCHEMBL4412351 | 0.78 | GRM2 (0.42) | GRM2 | |
| SCHEMBL4415144 | 0.78 | MAPT (0.55) | GBA1 | |
| SCHEMBL4416743 | 0.78 | GRM2 (0.42) | GRM2 | |
| SCHEMBL4416905 | 0.77 | ALDH1A1 (0.47) | GBA1 | |
| SCHEMBL4420345 | 0.77 | ALDH1A1 (0.42) | GRM2 | |
| SCHEMBL4416390 | 0.76 | KDM4E (0.43) | GBA1 | |
| SCHEMBL4414810 | 0.76 | ALDH1A1 (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1397351-B1 | PYRIMIDINE, TRIAZINE AND PYRAZINE DERIVATIVES AS GLUTAMATE RECEPTORS | HOFFMANN LA ROCHE (CH) | 2009-11-11 | — | — | EP | disclosed |
| EP-1397351-A1 | PYRIMIDINE, TRIAZINE AND PYRAZINE DERIVATIVES AS GLUTAMATE RECEPTORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-03-17 | — | — | EP | disclosed |
| US-6673795-B2 | SUCH AS 6-(4-(4-FLUORO-PHENYL)-PIPERAZIN-1-YL)-2-METHYL-5-NITRO-3-(2,2,2-TRIFLUORO -ETHYL)-3H-PYRIMIDIN-4-ONE, WHICH ARE METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS USEFUL IN TREATING PSYCHOLOGICAL DISORDERS | HOFFMANN-LA ROCHE INC. | 2004-01-06 | — | — | US | disclosed |
| US-20030060466-A1 | Pyrimidine, pyrazine and triazine derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2003-03-27 | — | — | US | disclosed |
| WO-2002098864-A1 | PYRIMIDINE, TRIAZINE AND PYRAZINE DERIVATIVES AS GLUTAMATE RECEPTORS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030060466-A1 | Pyrimidine, pyrazine and triazine derivatives | P2RX5, IL5, P2RX2 | GRM2 441/4885NTSR1 393/4885GBA1 2208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.